Longitudinal analysis of complete blood count parameters in advanced‐stage lung cancer patients

Rojko, Livia and Megyesfalvi, Zsolt and Czibula, Eszter and Reiniger, Lilla and Teglasi, Vanda and Szegedi, Zsolt and Szallasi, Zoltan and Dome, Balazs and Moldvay, Judit (2020) Longitudinal analysis of complete blood count parameters in advanced‐stage lung cancer patients. Thoracic Cancer, 11 (11). pp. 3193-3204. ISSN 1759-7706

Preview

Text megyesfalvi_2020.pdf - Published Version Available under License Creative Commons Attribution. Download (2MB) | Preview

Abstract

Background: Metastatic lung cancer is a debilitating disease, but with the advances in immunotherapy, therapeutic options have vastly increased. Numerous complete blood count parameters (CBC) have been described as easily accessible biomarkers that might predict response to immunotherapy. However, to date, no comprehensive study has been performed on the longitudinal changes of these parameters during cancer progression. Methods: The clinicopathological variables and CBC parameters of 986 advanced stage lung cancer patients were retrospectively analyzed. Blood tests were performed as part of the routine checkup and the results were recorded at the time of the diagnosis of the primary tumor, the diagnosis of brain or bone metastases, and also during the last available follow-up. Results: In the experimental subcohort, 352 and 466 patients were diagnosed with brain and bone metastases, respectively. The control group consisted of 168 patients without clinically detectable or other distant organ metastases. In our longitudinal analyses, we found significantly decreasing absolute lymphocyte count (ALC: P < 0.001), and significantly increasing absolute neutrophil count (ANC: P < 0.001) levels in all patient subgroups, irrespective of histopathological type and metastatic site. Interestingly, patients with brain metastases had significantly descending-ascending platelet count (PLT) trendlines (P < 0.001), while the bone metastatic subgroup exhibited significantly ascending-descending trendlines (P = 0.043). Conclusions: Significantly decreasing ALC, significantly increasing ANC and fluctuating PLT levels may be found in brain and bone metastatic lung cancer patients during disease progression. Our findings might contribute to improve personalized healthcare in this devastating malignancy.

Actions (login required)

Edit Item